SMMT

18.98

3.66% 0.67

Dopo l'orario di chiusura: 19.03 0.05 +0.26%

Summit Therapeutics Inc (SMMT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SMMT Giù? Forum Previsione

Precedente Chiudi:

$18.31

Aprire:

$18.36

Volume 24 ore:

1.39M

Relative Volume:

0.28

Capitalizzazione di mercato:

$14.00B

Reddito:

$956.00K

Utile/perdita netta:

$-196.68M

Rapporto P/E:

-11.29

EPS:

-1.6811

Flusso di cassa netto:

$-113.02M

1 W Prestazione:

-12.82%

1M Prestazione:

-10.51%

6M Prestazione:

+327.48%

1 anno Prestazione:

+883.42%

Intervallo 1D:

$18.11

$19.25

Intervallo di 1 settimana:

$18.11

$22.25

Portata 52W:

$1.89

$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Nome

Summit Therapeutics Inc

Settore

Healthcare (1204)

Industria

Biotechnology (683)

Telefono

305-203-2034

Indirizzo

601 BRICKELL KEY DRIVE, MIAMI

Dipendente

105

Cinguettio

@summitplc

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

SMMT's Discussions on Twitter

Confronta SMMT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SMMT	18.98	14.00B	956.00K	-196.68M	-113.02M	-1.6811
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2018-06-28	Downgrade	Janney	Buy → Neutral
2018-05-02	Iniziato	Janney	Buy
2018-04-12	Reiterato	Needham	Buy
2018-02-13	Iniziato	BTIG Research	Buy
2018-01-04	Iniziato	SunTrust	Buy
2017-12-01	Ripresa	H.C. Wainwright	Buy
2016-11-16	Reiterato	RBC Capital Mkts	Outperform
2016-10-05	Reiterato	Needham	Buy
2016-09-16	Iniziato	H.C. Wainwright	Buy
2015-03-30	Iniziato	Needham	Buy
2015-03-30	Iniziato	Oppenheimer	Outperform

Mostra tutto

Summit Therapeutics Inc Borsa (SMMT) Ultime notizie

08:32 AM

Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

08:32 AM

Nov 17, 2024

(SMMT) Trading Report - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

Here's Merck's $3.3 Billion Insurance Against Summit's Advance - Investor's Business Daily

Nov 14, 2024

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters

Nov 14, 2024

Nov 13, 2024

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga

Nov 09, 2024

Is Summit Therapeutics a Millionaire Maker? - AOL

Nov 09, 2024

Nov 08, 2024

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 08, 2024

Why Summit Therapeutics Stock Was a Winner Today - MSN

Nov 08, 2024

Nov 06, 2024

Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily

Nov 06, 2024

Nov 04, 2024

SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com

Nov 04, 2024

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN

Nov 04, 2024

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK

Nov 04, 2024

Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com

Nov 04, 2024

Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK

Nov 04, 2024

Summit Therapeutics Leads The Parade Of Big Gainers - Forbes

Nov 04, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat

Nov 04, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN

Nov 04, 2024

Nov 03, 2024

3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool

Nov 03, 2024

Nov 01, 2024

abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Nov 01, 2024

Oct 31, 2024

H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada

Oct 31, 2024